Giant Cell Arteritis Clinical Trials 2023

Giant Cell Arteritis Clinical Trials 2023

Giant Cell Arteritis research studies recruiting patients in 2023 need your help. Receive premium care & cutting edge treatments by enrolling in giant cell arteritis clinical trials today.

Popular filter options for giant cell arteritis trials

Frequently Asked Questions

Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the 'trial drug' — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
Is there any support for travel costs?
Many of the teams running clinical trials will cover the cost of transportation to-and-from their care center.
Will I know what medication I am taking?
This depends on the specific study. If you're worried about receiving a placebo, you can actively filter out these trials using our search.
How long do clinical trials last?
Some trials will only require a single visit, while others will continue until your disease returns. It's fairly common for a trial to last somewhere between 1 and 6 months.
Do you verify all the trials on your website?
All of the trials listed on Power have been formally registered with the US Food and Drug Administration. Beyond this, some trials on Power have been formally 'verified' if the team behind the trial has completed an additional level of verification with our team.
How quickly will I hear back from a clinical trial?
Sadly, this response time can take anywhere from 6 hours to 2 weeks. We're working hard to speed up how quickly you hear back — in general, verified trials respond to patients within a few days.

Introduction to giant cell arteritis

What are the top hospitals conducting giant cell arteritis research?

When it comes to cutting-edge clinical trials in the realm of giant cell arteritis, several hospitals are leading the way. Novartis Investigative Site has established three separate locations that prioritize research in this field: Saint Clair Shores, Spring, and Boston. Each site is currently conducting two active trials for giant cell arteritis and has a combined track record of two completed studies. These sites have recently emerged as key players in the fight against this complex condition, with their first recorded trial taking place in 2021.

Meanwhile, at the University of Pennsylvania in Philadelphia, researchers are also making significant strides in understanding and treating giant cell arteritis. This esteemed institution currently has two ongoing clinical trials focused on this disease while having an impressive history of seven completed trials dating back to 2006 when they began investigating this specific condition.

In addition to these institutions, Mayo Clinic located in Rochester holds equal expertise and commitment towards studying giant cell arteritis through its own pair of active clinical trials alongside them recording total participation since as early as 1995 bolstering their experience carrying out similar seven manner experiments successfully.

Giant cell arteritis poses complex challenges for both patients and clinicians alike; however, with dedicated hospitals like these actively pursuing novel treatments through rigorous clinical trials across various locations nationwide—patients can find solace knowing that progress is being made toward improving outcomes for those affected by this debilitating condition.

Which are the best cities for giant cell arteritis clinical trials?

When it comes to giant cell arteritis clinical trials, several cities have emerged as prominent locations for research and development. Philadelphia, Pennsylvania leads the way with three active trials focused on investigating treatments like Abatacept, Upadacitinib, and Naltrexone Hydrochloride. Following closely behind are Atlanta, Georgia; Saint Clair Shores, Michigan; Spring, Texas; and Boston Massachusetts with two active trials each exploring treatment options such as Secukinumab 300 mg and others. These cities serve as vital hubs for individuals seeking participation in cutting-edge clinical trials that aim to advance our understanding of giant cell arteritis and improve patient care outcomes.

Which are the top treatments for giant cell arteritis being explored in clinical trials?

Exciting developments are underway in the clinical trials for giant cell arteritis, with several top treatments showing promise. Leading the pack is secukinumab 300 mg, currently being explored in two active trials dedicated to this condition. Guselkumab and abatacept also hold potential as they each have one active trial focusing on giant cell arteritis. In addition, 68-Ga HA-DOTATATE PET/CT and upadacitinib are emerging contenders with one ongoing trial for each treatment option. These innovative approaches offer hope for improved management of giant cell arteritis and may bring new avenues of treatment to patients worldwide.

What are the most recent clinical trials for giant cell arteritis?

Exciting advancements in the field of giant cell arteritis have emerged from recent clinical trials, offering hope for improved treatment options. One such trial investigated the efficacy of Secukinumab 300 mg, reaching Phase 3 and becoming available on March 22, 2023. This promising study builds upon previous research conducted with Secukinumab and its potential benefits in managing this condition. Additionally, Abatacept has also shown promise as a potential treatment for giant cell arteritis during its Phase 3 trial which became available on March 15, 2021. These developments bring renewed optimism to those affected by giant cell arteritis as researchers continue to explore innovative therapeutic approaches that may alleviate symptoms and enhance patient outcomes.

What giant cell arteritis clinical trials were recently completed?

In November 2018, Massachusetts General Hospital wrapped up a clinical trial investigating the efficacy of Tocilizumab in treating giant cell arteritis. This study represents one of the most recent completed trials for this condition.